INVOKANA®: an SGLT2 inhibitor that helps relieve the burden of sugar for your patients1,3,4

Only INVOKANA® offloads ~100 grams of glucose per day through its mechanism of action1,3,4

INVOKANA®
~100 grams per day (at 100 mg or 300 mg)1

There have been no head-to-head clinical trials comparing the efficacy or safety of SGLT2 inhibitors. No direct evaluation of comparative clinical profiles can be made.

Farxiga® (dapagliflozin) Jardiance® (empagliflozin)
~70 grams per day (at 5 mg or 10 mg)3

~64 grams per day (at 10 mg)4
~78 grams per day (at 25 mg)4

Urinary glucose excretion rates shown are from the Prescribing Information for each marketed SGLT2 inhibitor.*

Steglatro™ (ertugliflozin) at 5 mg and at 15 mg did not report urinary glucose excretion in its Prescribing Information.5

Indicated trademarks are registered trademarks of their respective owners.

*In single-dose pharmacokinetic/pharmacodynamic studies in healthy people and in patients with type 2 diabetes.

SGLT2=sodium-glucose co-transporter 2.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34-42. 3. Farxiga® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 4. Jardiance® [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 5. Steglatro™ [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.